शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
ACUTAASBSEACUTAAS CHEMICALS LIMITED· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 24 Jul, 2026 · 12:31 IST

ACUTAAS Q1 FY27: Revenue up 59 percent YoY, PAT up 70 percent

Revenue Growth 20pctPat Growth 25pctResults View source PDFExplain this filing

ACUTAAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-5.1%Reaction day
₹3425.00
prior close
₹3439.00
announcement price
In-mkt
timing
Nifty Smallcap 250market-0.3%-4.8% vs market
Pharmaceuticals peers, median of 164sector-0.1%-5.0% vs sector

On the reaction day the stock moved 4.8 pts less than Nifty Smallcap 250 and 5.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-3.1
10m
-3.8
15m
-4.7
30m
-4.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-5.1-0.3-4.8-0.1-5.0
Next day
-2.2+1.0-3.1+0.6-2.7
2d
-1.3+0.5-1.8+0.1-1.3
3d
-3.6+1.9-5.5+0.6-4.3
4d
-5.6+1.1-6.7-0.0-5.6
5d
-9.8+1.5-11.4+0.2-10.0
1w
-5.7+3.1-8.8+0.8-6.5
15d
-5.7+3.6-9.3+2.7-8.5
1m
-7.4+4.1-11.5+1.4-8.9
2m
-3.8+2.9-6.7+4.1-7.9
3m
-2.2-6.1+3.9-4.2+2.0
UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

ACUTAAS CHEMICALS (formerly Ami Organics) posted strong Q1 FY27 results. Consolidated revenue from operations rose about 59 percent YoY to Rs 329.67 crore (from Rs 207.24 crore). Consolidated PAT grew about 70 percent YoY to Rs 74.99 crore (from Rs 44.01 crore). Standalone revenue rose about 57 percent YoY to Rs 322.41 crore with PAT at Rs 75.90 crore. No exceptional items. Auditor gave an unmodified limited review. Subsidiary ACEPL diluted from 100 percent to 90 percent after a preferential issue.

Likely market impact

Strong YoY growth in revenue and profit signals healthy demand and momentum; sequential dip from Q4 reflects typical seasonality for chemicals.